Creative Touch Permanent Makeup and Aesthetics

The clinical framework for elastin treatments differs fundamentally from the collagen framework. Where collagen strategy centres on stimulating synthesis and controlling MMP degradation in roughly equal measure, elastin strategy requires a third consideration upfront: the state of the fibrillin microfibril scaffold that newly synthesised tropoelastin must deposit onto. A treatment that successfully stimulates tropoelastin production in tissue where the scaffold is degraded produces limited elastic fibre recovery regardless of how much new protein is expressed.

This means treatment selection for elastin is best structured around three questions: Is there significant solar elastotic material present that is actively interfering with normal elastic fibre organisation? Is the fibrillin scaffold sufficiently intact to support new elastic fibre assembly? And which pathway to fibroblast activation is most appropriate given the inflammatory context of the tissue?

Clearing the Path: Fractional RF and the Solar Elastosis Problem

For photodamaged skin with visible signs of solar elastosis, the priority is not simply stimulating new elastin – it is removing the dysfunctional accumulated material and creating the structural environment in which newly synthesised tropoelastin can assemble correctly. This is where fractional radiofrequency produces its most distinctive elastin benefit.

A biopsy-confirmed clinical study on combined microneedling and sublative fractional RF treatment found statistically significant restoration of normal-appearing elastic fibres alongside a significant reduction in abnormal elastin at three months, with p = 0.0005 for the abnormal elastin reduction. This is the RF paradox resolved in clinical histology: the treatment exchanges degraded, non-functional elastin accumulation for a smaller quantity of properly organised elastic fibres. For clients with heavily photodamaged or significantly aged skin, this outcome represents a genuine structural improvement even though total elastin content may not increase dramatically. ^[4]

RF energy’s thermal mechanism is particularly relevant for elastin because the fibrillin scaffold itself responds to controlled heat exposure. Thermal injury in the papillary and reticular dermis triggers a fibroblast activation cascade that includes fibrillin-1 expression alongside tropoelastin production, partially restoring the assembly infrastructure that makes new elastic fibre formation possible. In acne scar tissue, where the dermal architecture is significantly disrupted, fractional RF has demonstrated histological evidence of elastic fibre regeneration alongside reduction of dermal fibrosis – confirming that the treatment can remodel the fibrillar environment rather than simply stimulating synthesis into unchanged tissue. scirp

RF Microneedling: Two Depths, Two Mechanisms

RF microneedling contributes to elastin recovery through both its needling and radiofrequency components, which operate at different tissue depths and on different timelines.

The needling-driven wound healing cascade stimulates fibroblast activation across the treated zone, with TGF-β signalling supporting tropoelastin transcription alongside collagen synthesis as part of the general repair response. The radiofrequency thermal component, delivered into the mid-to-deep dermis via the needle tips, reaches depths where the elastic fibre network is more likely to be structurally intact, creating the thermal remodelling signal at the level where new fibre assembly can be supported by surviving fibrillin infrastructure. The combination produces both the abnormal elastin clearing effect associated with surface fractional RF and the deeper fibroblast activation associated with needling. For clients with mixed presentations – some solar elastosis alongside general laxity from age-related elastin decline – this combined mechanism addresses more of the clinical picture than either component alone.

iPRF: Growth Factor Support for a Slow Process

iPRF contributes to elastin recovery through growth factor delivery, though the evidence base here is more appropriately described as mechanistically plausible than fully characterised for elastin specifically. The TGF-β, PDGF, and IGF-1 released from platelet concentrates all have established fibroblast activation roles, and the significantly elevated TGF-β and fibronectin mRNA expression demonstrated with iPRF versus PRP supports a more complete fibroblast activation environment. Fibronectin is specifically relevant to elastin assembly: it supports tropoelastin deposition onto the fibrillin scaffold during early elastic fibre formation, making it a useful co-factor in the assembly pathway rather than just a general matrix protein. ^[10]

The honest framing for iPRF and elastin is: it creates a growth factor environment highly conducive to whatever elastin synthesis capacity remains in the tissue, and it supports the matrix protein production that makes assembly possible – but it does not directly address solar elastotic material or degraded fibrillin scaffold. For maximum elastin benefit, iPRF is most rationally paired with RF or RF microneedling rather than used in isolation for elastin-specific concerns.

Polynucleotides: Elasticity Via the Macrophage Axis

The in vivo polynucleotide research that characterised the macrophage PCK1 mechanism for collagen also measured skin elasticity as an outcome, finding significant improvement in skin elasticity over the treatment period alongside collagen density increases. The mechanism extends naturally to elastin: M2 macrophage polarisation and IL-10/TGF-β secretion drive fibroblast activation broadly, and the NF-κB suppression that reduces MMP-driven collagen degradation simultaneously reduces the MMP elastase activity that degrades elastic fibres and their fibrillin scaffold. Polynucleotides do not specifically target tropoelastin transcription, but the combined effect of activated fibroblasts, reduced elastase activity, and a calmer inflammatory environment creates conditions in which whatever residual elastin synthesis capacity exists can function more effectively. ^[2]

For clients with senescent fibroblasts – the perimenopausal and post-menopausal presentation, or significantly photo-aged skin – polynucleotides’ route through macrophage reprogramming to reach senescent fibroblasts is particularly relevant, because direct fibroblast stimulation approaches become progressively less effective as fibroblast responsiveness declines with age. ^[2]

PLLA: A Modest but Real Elastin Contribution

PLLA’s primary clinical value in this context is collagen neogenesis rather than elastin-specific intervention, and it should be framed as such. However, its direct PI3K/AKT fibroblast activation upregulates tropoelastin production alongside Type I and III collagen synthesis as part of the broader fibroblast capacity restoration it drives. ^[6] For clients undergoing a PLLA course primarily for structural collagen decline, this elastin contribution is a genuine secondary benefit rather than an incidental one – particularly in the post-menopausal presentation where the fibroblast senescence that limits collagen output is simultaneously limiting whatever residual tropoelastin synthesis capacity remains. PLLA does not address solar elastotic material, does not remodel the fibrillin scaffold, and does not replace the clearing and remodelling role of RF microneedling for elastin-specific presentations. Where it adds value is in the senescent fibroblast environment, restoring the cellular capacity that makes any elastin synthesis at all possible – as the endpoint of a protocol rather than its starting point.

Treatment Pairings for Elastin

Because elastin recovery requires clearing degraded material, supporting the scaffold, and stimulating synthesis in that logical sequence, combination approaches outperform any single modality.

For photoaged/solar elastosis presentations: Fractional RF or RF microneedling as the primary treatment (clearing abnormal elastin, thermal scaffold remodelling), combined with iPRF in the same session (growth factor support for new fibre assembly), with polynucleotides as a separate preparatory or interval treatment to reduce the MMP-elastase burden before the RF session. The sequencing matters: resolving the inflammatory elastase environment before thermal treatment allows the wound-healing response to operate into a less destructive extracellular environment.

For age/hormonal-related laxity without significant solar elastosis: RF microneedling primary (fibroblast activation at appropriate depth, TGF-β signalling for tropoelastin and fibrillin), combined with polynucleotides (macrophage axis fibroblast activation, NF-κB/MMP suppression), with iPRF as an enhancing co-treatment. This combination targets the fibroblast activation signal from three independent pathways simultaneously – wound cascade, macrophage-fibroblast axis, and growth factor delivery – giving the limited elastin synthesis capacity of adult fibroblasts the strongest possible stimulus from multiple angles. For clients where fibroblast senescence is prominent – post-menopausal presentations, or where previous stimulation treatments have underdelivered – PLLA can be incorporated as a longer-horizon course running alongside or between RF microneedling sessions, partially restoring the fibroblast capacity that determines how effectively both the elastin and collagen synthesis signals are acted upon. ^[6]

The homecare layer that applies to both: No professional treatment for elastin achieves its potential without consistent broad-spectrum UV protection, which prevents new MMP-12 activity from degrading both the treated tissue and the fibrillin scaffold between sessions. Topical antioxidants, particularly vitamin C and vitamin E, reduce the ROS-driven AP-1 signalling that upregulates MMP transcription. Retinoids reduce MMP expression broadly.

Vitamin K2 – specifically MK-4 and MK-7 – adds a third homecare mechanism that is distinct from both UV protection and antioxidant MMP suppression. Through γ-glutamyl carboxylase (GGCX)-dependent carboxylation of matrix Gla protein (MGP), K2 prevents the deposition of calcium into elastic fibres; a progressive mineralisation process that reduces elastin’s stretch-and-recoil capacity through stiffening rather than degradation. Where glycation drives collagen rigidity through AGE cross-linking and UV-driven MMP-12 degrades the elastic fibre network, elastin calcification represents a third parallel stiffening mechanism operating independently of both. Adequate K2 status does not reverse established calcification – carboxylated MGP prevents further deposition rather than dissolving existing mineral deposits – making early and sustained supplementation more protective than remedial. For clients managing elastin decline comprehensively, MK-7 at 100–200 µg daily addresses this calcification pathway alongside the UV protection and antioxidant protocols addressing the other two.

For elastin specifically, this homecare layer is not supplementary to professional treatment, it is the maintenance environment that determines whether the improvement achieved in clinic is preserved or progressively lost between sessions. ^[9]